Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
Commentary

Suzetrigine: A novel nonopioid systemic analgesic

Anthony E. Divito, MD, Matthew Sharobeem, DO, Gausan R. Bajracharya, MD and Basem B. Abdelmalak, MD
Cleveland Clinic Journal of Medicine February 2026, 93 (2) 94-98; DOI: https://doi.org/10.3949/ccjm.93a.25087
Anthony E. Divito
Department of Anesthesiology, Cleveland Clinic, Cleveland, OH; Temporary Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Sharobeem
Department of Internal Medicine, McLaren Port Huron Hospital, Port Huron, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gausan R. Bajracharya
Department of Anesthesiology, Cleveland Clinic, Cleveland, OH; Member, Outcomes Research Consortium, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Basem B. Abdelmalak
Director, Anesthesia for Bronchoscopic Surgery, Department of Anesthesiology, Cleveland Clinic, Cleveland, OH; Chair, Executive Enterprise Procedural Sedation Committee, Cleveland Clinic, Cleveland, OH; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Member, Outcomes Research Consortium, Houston, TX; Past President, Society for Ambulatory Anesthesia (SAMBA); Chair, American Society of Anesthesiologists (ASA) Taskforce on Non-Operating Room Anesthesia and Procedural Sedation; Co-Chair, ASA Taskforce on Pre-Operative Fasting Guidelines
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: abdelmb{at}ccf.org
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Suzetrigine prescribing and cost information

    IndicationApproved by US Food and Drug Administration to treat acute postoperative pain for 14 days
    DoseLoading: 100 mg
    Maintenance: 50 mg every 12 hours
    DurationHalf-life of 23.6 hours
    Cost$15.50 per pill18 (typical course is 2 weeks)
    Common side effectsNausea and vomiting, pruritis, rash, muscle spasms, increased serum creatine phosphokinase level
    ContraindicationsHormonal contraceptives: may impair efficacy
    Cirrhosis: reduce dose for Child-Pugh class B; do not use in Child-Pugh class C
    CYP3A substrates: inhibitors may cause accumulation of drug and metabolites; inducers may reduce effect
    • Based on information from reference 11.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 93 (2)
Cleveland Clinic Journal of Medicine
Vol. 93, Issue 2
1 Feb 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Suzetrigine: A novel nonopioid systemic analgesic
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
Suzetrigine: A novel nonopioid systemic analgesic
Anthony E. Divito, Matthew Sharobeem, Gausan R. Bajracharya, Basem B. Abdelmalak
Cleveland Clinic Journal of Medicine Feb 2026, 93 (2) 94-98; DOI: 10.3949/ccjm.93a.25087

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Suzetrigine: A novel nonopioid systemic analgesic
Anthony E. Divito, Matthew Sharobeem, Gausan R. Bajracharya, Basem B. Abdelmalak
Cleveland Clinic Journal of Medicine Feb 2026, 93 (2) 94-98; DOI: 10.3949/ccjm.93a.25087
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • THE FIRST SYSTEMIC SODIUM CHANNEL BLOCKER ORAL ANALGESIC
    • PHARMACODYNAMICS AND PHARMACOKINETICS
    • FDA APPROVAL PROCESS FOR NEW PAIN MEDICATIONS
    • PAIN MANAGEMENT EFFECTIVENESS
    • SIDE EFFECTS
    • FDA LABELING REQUIREMENTS
    • OPPORTUNITIES AND LIMITATIONS
    • CONCLUSION
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A new direction in pain management?
  • Google Scholar

More in this TOC Section

  • Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily
  • Vaccine hesitancy: Where are we heading?
Show more Commentary

Similar Articles

Subjects

  • Drug Therapy
  • Hospital Medicine
  • Pain

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2026 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire